The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tsygankov B.D.

Moskva

Agasarian É.G.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

The comparative efficacy of therapy with typical and atypical antipsychotics

Authors:

Tsygankov B.D., Agasarian É.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(9): 83‑86

Read: 2859 times

Download PDF (RU)
Contact the author
Table of contents

THE COMPARATIVE EFFICACY OF THERAPY WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS
THE COMPARATIVE EFFICACY OF THERAPY WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS

To cite this article:

Tsygankov BD, Agasarian ÉG. The comparative efficacy of therapy with typical and atypical antipsychotics. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(9):83‑86. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Keywords:

typical antipsychotics
atypical antipsychotics
neuroleptics
schizophrenia treatment
typical antipsychotics
atypical antipsychotics
neuroleptics
schizophrenia treatment

Authors:

Tsygankov B.D.

Moskva

Agasarian É.G.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Close metadata

References:

  1. Tsygankov B.D., Agasaryan E.G. Analiz effektivnosti i bezopasnosti sovremennykh i klassicheskikh antipsikhoticheskikh preparatov. Zhurn nevrol i psikhiat 2006; 106: 9: 64-70.
  2. Casey D.E. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006; 11: Suppl 7: 25-31.
  3. Essock S.M., Covell N.H., Davis S.M. et al. Effectiveness of switching antipsychotic medications. Am J Psychiat 2006; 163: 2090-2095.
  4. Freedman R., Carpenter W.T., Davis J.M. et al. The costs of drugs for schizophrenia. Am J Psychiat 2006; 163: 2029-2031.
  5. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376.
  6. Janicak P.G. The CATIE study and its implications antipsychotic drug use. Essent Psychopharmacol 2006; 7: 53-63.
  7. Jones P.B., Barnes T.R., Davies L. et al. Randomized controlled trial of the effect and quality of life of second- vs first- generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiat 2006; 63: 1079-1087.
  8. Kahn R.S., Fleischhacker W.W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia an schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371-1085-97.
  9. Kane J.M. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiat 2006; 67: 831-832.
  10. Kasper S., Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiat 2006; 7: 126-127.
  11. Keefe R.S., Bilder R.M., Davis S.M. et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiat 2007; 64: 633-647.
  12. Lambert M., Schimmelmann B.G., Naber D. et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiat 2006; 67: 11: 1690-1697.
  13. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68.
  14. Leucht S., Corves C., Arbter D. et al. Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
  15. Leucht S., Komossa K., Rummel-Kluge C. et al. A head to head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiat 2009; 166: 152-163.
  16. Lewis S.W., Barnes T.R., Davies L. et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-723.
  17. Lewis S.W., Davies L., Jones P.B. et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006; 10: 17: 1-182.
  18. Liberman J.A., Stroup T.S., McEvoy J.P. et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 12: 1209-1223.
  19. Meltzer H.Y., Bobo W.V. Interpreting the efficacy findings in the CATIE study: what the clinician should know. CNS Spectr 2006; 11: Suppl 7: 14-24.
  20. Moller H.-J. Do effectiveness studies tell us the real truth? The World J Biol Psychiat 2007; 8: 3: 138-140.
  21. Naber D., Lambert M. The CATIE and CUTlass studies in schizophrenia. CNS drugs 2009; 23: 8: 649-659.
  22. Rosenheck R.A., Leslie D.L., Doshi G.A. Second generation antypsichotics: cost effectiveness, policy options and political decision making. Psychiat Serv 2008; 59: 515-520.
  23. Rosenheck R.A., Leslie D.L., Sindelar J. et al. Cost effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiat 2006; 163: 2080-2089.
  24. Rosenheck R., Stroup S.T., Keefe R.S.E. et al. Study samples key to assessing risk. The authors reply. Curr Psychiat 2007; 6: 1: 3-19.
  25. Swartz M.S., Perkins D.O., Stroup S.T. et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiat 2007; 164: 428-436.
  26. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: What does CATIE tell us? - part 1. Int Drug Ther Newsl 2006; 41: 51-58.
  27. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what does CATIE tell us? - part 2. Int Drug Ther Newsl 2006; 41: 67-74.
  28. Tandon R., Carpenter W.T., Davis J.M. First- and secondgeneration antipsychotics: Learning from CUtLASS and CATIE. Arch Gen Psychiat 2007; 64: 977-978.
  29. Tandon R., Constantine R.J. Avoiding EPS is the key to realizing "atypical" benefits. Curr Psychiat 2006; 5: 11: 35-45.
  30. Tyrer P., Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 3: 373: (9657): 4-5.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.